Racecadotril for organ injury in sepsis patients
Part of Infections clinical trials.
This trial tests if Racecadotril, a medication that may protect organs from damage, can help people with sepsis (a severe infection that affects the whole body). It is for patients who are in the hospital and have a certain level of organ injury.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have sepsis with a specific level of organ injury (doctors will check this using a score called SOFA-2).
- You must be able to receive liquid nutrition through a tube into your stomach or intestine.
- You must not have severe liver or kidney problems that would affect the study.
- You cannot be taking certain medications like erythromycin, ketoconazole, or rifampicin.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug, AZD4144, can help people with sepsis-related acute kidney injury in the ICU. It aims to see if the drug can improve kidney recovery and reduce complications.
This trial tests if adding an iron chelator (MEX-CD1) to the dialysis fluid can help remove harmful iron from the blood in patients with sepsis-related acute kidney injury who need continuous dialysis. It may reduce damage to the kidneys and other organs.
This trial tests if a special fluid given through a vein can protect and repair the lining of your blood vessels during sepsis. Sepsis is a dangerous reaction to an infection that can damage organs. This study aims to see if this treatment helps patients in the intensive care unit (ICU) recover better.
This trial studies whether early tranexamic acid (a medicine that can reduce bleeding) can change the body’s inflammatory response in people with sepsis. If it works, it may help improve outcomes for certain ICU patients—but you must meet specific safety and eligibility checks.
This trial tests a new medicine called YD0743 for people who have both sepsis (a serious infection) and ARDS (a severe lung injury from the infection). The goal is to see if the medicine helps improve breathing and survival.
This trial studies whether a “remote preconditioning” treatment given during early sepsis can help protect the kidneys and improve outcomes. It is for adults in the ICU very soon after sepsis begins.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.